517 related articles for article (PubMed ID: 36827874)
1. A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.
Stoll S; Desai S; Levit E
Mult Scler Relat Disord; 2023 Mar; 71():104574. PubMed ID: 36827874
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
[TBL] [Abstract][Full Text] [Related]
3. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
[TBL] [Abstract][Full Text] [Related]
4. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
[TBL] [Abstract][Full Text] [Related]
5. Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies.
Wallach AI; Schiebel M; Picone MA
Mult Scler Relat Disord; 2022 Jul; 63():103856. PubMed ID: 35636275
[TBL] [Abstract][Full Text] [Related]
6. Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?
Jeantin L; Abdi B; Soulié C; Sterlin D; Maillart E; Beigneux Y; Hippolyte A; Belin L; Marcelin AG; Pourcher V; Louapre C
J Neurol Neurosurg Psychiatry; 2023 Dec; 95(1):19-28. PubMed ID: 37479463
[TBL] [Abstract][Full Text] [Related]
7. Three to four mRNA COVID-19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralization.
Louapre C; Belin L; Marot S; Hippolyte A; Januel E; Ibrahim M; Jeantin L; Zafilaza K; Malet I; Charbonnier-Beaupel F; Rosenzwajg M; Soulié C; Marcelin AG; Pourcher V
Eur J Neurol; 2023 Sep; 30(9):2781-2792. PubMed ID: 37310391
[TBL] [Abstract][Full Text] [Related]
8. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies.
Boekel L; Steenhuis M; Hooijberg F; Besten YR; van Kempen ZLE; Kummer LY; van Dam KPJ; Stalman EW; Vogelzang EH; Cristianawati O; Keijzer S; Vidarsson G; Voskuyl AE; Wieske L; Eftimov F; van Vollenhoven R; Kuijpers TW; van Ham SM; Tas SW; Killestein J; Boers M; Nurmohamed MT; Rispens T; Wolbink G
Lancet Rheumatol; 2021 Nov; 3(11):e778-e788. PubMed ID: 34396154
[TBL] [Abstract][Full Text] [Related]
9. Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab.
Katz JD; Bouley AJ; Jungquist RM; Douglas EA; O'Shea IL; Lathi ES
Mult Scler Relat Disord; 2022 Jan; 57():103382. PubMed ID: 35158475
[TBL] [Abstract][Full Text] [Related]
10. Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis.
Schwarz T; Otto C; Jones TC; Pache F; Schindler P; Niederschweiberer M; Schmidt FA; Drosten C; Corman VM; Ruprecht K
Mult Scler; 2022 Jun; 28(7):1041-1050. PubMed ID: 35575234
[TBL] [Abstract][Full Text] [Related]
11. Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies.
Alfonso-Dunn R; Lin J; Kirschner V; Lei J; Feuer G; Malin M; Liu J; Roche M; Sadiq SA
Front Immunol; 2022; 13():926318. PubMed ID: 35990701
[TBL] [Abstract][Full Text] [Related]
12. Post-vaccination SARS-Cov-2 T-cell receptor repertoires in patients with multiple sclerosis and related disorders.
Algu P; Hameed N; DeAngelis T; Stern J; Harel A
Mult Scler Relat Disord; 2023 Nov; 79():104965. PubMed ID: 37657307
[TBL] [Abstract][Full Text] [Related]
13. B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients.
Asplund Högelin K; Ruffin N; Pin E; Hober S; Nilsson P; Starvaggi Cucuzza C; Khademi M; Olsson T; Piehl F; Al Nimer F
Eur J Neurol; 2022 Nov; 29(11):3317-3328. PubMed ID: 35808856
[TBL] [Abstract][Full Text] [Related]
14. Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab.
Groß-Albenhausen E; Weier A; Velten M; Heider T; Chunder R; Kuerten S
Front Immunol; 2023; 14():1254128. PubMed ID: 37841269
[TBL] [Abstract][Full Text] [Related]
15. Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications - A pilot study.
Moser T; Otto F; O'Sullivan C; Hitzl W; Pilz G; Harrer A; Trinka E; Wipfler P
Mult Scler Relat Disord; 2022 Mar; 59():103560. PubMed ID: 35093840
[TBL] [Abstract][Full Text] [Related]
16. Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?
Baker D; MacDougall A; Kang AS; Schmierer K; Giovannoni G; Dobson R
Clin Exp Immunol; 2022 May; 207(3):263-271. PubMed ID: 35553629
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 Vaccine Response in People with Multiple Sclerosis.
Tallantyre EC; Vickaryous N; Anderson V; Asardag AN; Baker D; Bestwick J; Bramhall K; Chance R; Evangelou N; George K; Giovannoni G; Godkin A; Grant L; Harding KE; Hibbert A; Ingram G; Jones M; Kang AS; Loveless S; Moat SJ; Robertson NP; Schmierer K; Scurr MJ; Shah SN; Simmons J; Upcott M; Willis M; Jolles S; Dobson R
Ann Neurol; 2022 Jan; 91(1):89-100. PubMed ID: 34687063
[TBL] [Abstract][Full Text] [Related]
18. Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study.
Madelon N; Lauper K; Breville G; Sabater Royo I; Goldstein R; Andrey DO; Grifoni A; Sette A; Kaiser L; Siegrist CA; Finckh A; Lalive PH; Didierlaurent AM; Eberhardt CS
Clin Infect Dis; 2022 Aug; 75(1):e1037-e1045. PubMed ID: 34791081
[TBL] [Abstract][Full Text] [Related]
19. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
20. Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab.
Madelon N; Heikkilä N; Sabater Royo I; Fontannaz P; Breville G; Lauper K; Goldstein R; Grifoni A; Sette A; Siegrist CA; Finckh A; Lalive PH; Didierlaurent AM; Eberhardt CS
JAMA Neurol; 2022 Apr; 79(4):399-404. PubMed ID: 35212717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
